

***Fiscal Year 2023 Chronic Pain Management Research Program (CPMRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Exploration Award (CEA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-CPMRP-CEA</p>	<p>Independent investigators at all levels</p>	<ul style="list-style-type: none"> • Supports early-phase, proof-of-principle clinical trials and correlative studies, particularly those including complementary and integrative health methods. • Research must address one or both of the FY23 CPMRP CEA Focus Areas of chronification of pain and effectiveness or observational studies of novel or untested techniques/approaches/pathways to chronic pain management. • Explorative studies, innovative approaches, and stakeholder engagement are encouraged. • Preliminary data are not required for FY23 CPMRP CEA applications. • Studies evaluating opioid-based therapeutic interventions are not allowed. • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$250,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. 	<p>Pre-Application (Preproposal): August 21, 2023 5:00 p.m. Eastern time</p> <p>Application: November 9, 2023 11:59 p.m. Eastern time</p>
<p>Investigator-Initiated Research Award (IIRA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-CPMRP-IIRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Supports innovative research that will make an original and important contribution to the field of research, patient care, and/or quality of life. • Research must address one or more of the FY23 CPMRP IIRA Focus Areas of chronification of pain or development of non-opioid therapies and methods of treatment of chronic pain. • Partnering PI Option is available. • Multidisciplinary collaborations, innovative approaches, and stakeholder engagement are encouraged. • Clinical trials will not be funded. • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$900,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): August 21, 2023 5:00 p.m. Eastern time</p> <p>Application: November 9, 2023 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Outcomes Research Award (CORA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-CPMRP-CORA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Supports acceleration of evidence-based ideas and research into clinical applications (e.g., health care products, technologies, practice guidelines, models of care). • Research must address one or more of the FY23 CPMRP CORA Focus Areas of comparative effectiveness for evidence-based, efficacious interventions to manage or prevent chronic pain, implementation science for evidence-based efficacious interventions to manage or prevent chronic pain, observational studies related to chronic pain, or relationships between comorbidities and pain. • Must include preliminary and/or published data collected by the research team that support the rationale for the proposed study. • Key stakeholder engagement throughout the research process is highly encouraged. • Partnering PI Option is available. • Studies evaluating opioid-based therapeutic interventions are not allowed. • Animal studies are not allowed. • <i>Submission of a preproposal is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,400,000 for direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): August 21, 2023 5:00 p.m. Eastern time</p> <p>Application: November 9, 2023 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Pain Management Collaborative Clinical Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-CPMRP-PMCCRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Supports large-scale clinical trials that promote acceleration of evidence-based ideas and research into clinical applications (e.g., health care products, technologies, practice guidelines, models of care). • Research must address one or more of the FY23 CPMRP PMCCRA Focus Areas of comparative effectiveness for evidence-based, efficacious interventions to manage or prevent chronic pain or implementation science for evidence-based efficacious interventions to manage or prevent chronic pain. • Participation in working groups and cross project initiatives is expected. • Must include preliminary and/or published data collected by the research team that support the rationale for the proposed study. • Key stakeholder engagement throughout the research process is highly encouraged. • Multiple PI Option is encouraged, allowing up to five Partnering PIs. • <i>Submission of a preproposal is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The PMCCRA is structured as a planning base phase with an option phase for the clinical trial. • Maximum funding of \$500,000 for direct costs (plus indirect costs). For the base period; Maximum funding of \$3,000,000 for direct costs (plus indirect costs) for the clinical trial phase. • Maximum period of performance is 15 months.; Maximum period of performance for the clinical trial phase is 3 years. 	<p>Pre-Application (Preproposal): August 21, 2023 5:00 p.m. Eastern time</p> <p>Application: November 9, 2023 11:59 p.m. Eastern time</p>